How to Switch from Mounjaro to Ozempic: A Comprehensive Guide

Last reviewed: June 30, 2026

Last updated: June 30, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Switching from Mounjaro to Ozempic is a prescriber-managed change, and there is no published milligram-for-milligram conversion between the two — the amount of tirzepatide you were taking does not translate into an equivalent amount of semaglutide. Both are once-weekly injectable medications approved for type 2 diabetes, and that shared indication is the honest starting point for this question. The Mounjaro prescribing information indicates it as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. The Ozempic prescribing information carries three indications, all of which also require type 2 diabetes. Neither product is approved for weight management.

What Each Product Is Approved to Do

Mounjaro has a single indication: glycemic control in type 2 diabetes, in adults and in pediatric patients aged 10 and older. Its labeled maximum is 15 mg once weekly in adults and 10 mg once weekly in pediatric patients, and it is supplied in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg presentations.

Ozempic covers more regulatory ground within the same disease. Alongside glycemic control, it is indicated to reduce the risk of major adverse cardiovascular events — cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke — in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Its labeled maximum dosage is 2 mg once weekly.

Why People Change

The most common reasons are not clinical failure. Formulary changes, prior authorization denials, pharmacy supply, and out-of-pocket cost move more people between these products than efficacy does. When a plan drops one and covers the other, the switch is a coverage event that happens to have clinical consequences.

Some reasons are clinical. Those two additional Ozempic indications matter for someone with established cardiovascular disease or chronic kidney disease alongside type 2 diabetes, because they represent outcomes the FDA reviewed evidence for rather than inferred. Tolerability is the other genuine driver: gastrointestinal adverse reactions are common across this class, and an individual may do better on one agent than another for reasons that are not predictable in advance.

The Two Drugs Do Not Work the Same Way

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist. Semaglutide is a selective GLP-1 receptor agonist. Moving between them is not like switching between two versions of the same drug — you are removing activity at one receptor system entirely.

That difference is why the change tends to be felt, particularly by people who had reached a high tirzepatide dose. It also explains why the transition is a clinical decision rather than an administrative one, since glycemic control, other diabetes medications, and any insulin or insulin secretagogue in the regimen all interact with the change.

There Is No Dose Conversion Table

Neither label contains a conversion between tirzepatide and semaglutide, and none exists in the approved labeling for either product. Ozempic's initiation dosage is described in its label as a starting dosage for treatment initiation, not as a maintenance dosage and not as something selected on the basis of what a patient took previously. Its ceiling is 2 mg once weekly regardless of where someone was on the tirzepatide scale.

The practical implication is that anyone quoting you an equivalence — a specific tirzepatide dose "equals" a specific semaglutide dose — is offering something the evidence does not support. How a prescriber sequences a transition is their judgment, informed by your glycemic control, your other medications, your tolerance history, and your monitoring. It is not a lookup.

What the Head-to-Head Trial Actually Showed

These two molecules were compared directly in SURPASS-2, published in the New England Journal of Medicine. The open-label 40-week trial randomized 1,879 patients with type 2 diabetes to tirzepatide 5 mg, 10 mg, or 15 mg, or to semaglutide 1 mg. Mean baseline glycated hemoglobin was 8.28% and mean weight 93.7 kg.

Estimated mean reductions in glycated hemoglobin were 2.01, 2.24, and 2.30 percentage points across the three tirzepatide doses versus 1.86 percentage points with semaglutide, and tirzepatide was noninferior and superior at all three doses. Reductions in body weight were also greater with tirzepatide, with least-squares mean estimated treatment differences of −1.9 kg, −3.6 kg, and −5.5 kg. Two caveats matter when reading that as a reason not to switch: the comparator was semaglutide 1 mg rather than the 2 mg maximum now on the Ozempic label, and group averages do not predict what any one person experiences.

The Rule Everyone Should Know Before Switching

Do not overlap the two. Labeling across this class advises against concomitant use with other GLP-1 receptor agonists, and stacking a residual supply of one medication onto a newly started one is the most predictable way to turn a routine transition into a serious adverse event. If you have leftover product, tell the prescriber rather than working it into the schedule.

The same caution applies to compounded preparations. A compounded semaglutide or tirzepatide product is not an FDA-approved finished product and is not a generic version of either brand, and it should be part of the same disclosure to whoever is managing the change.

What the Conversation Should Cover

Bring the specifics: which product and strength you are on now, how long you have been on it, what your recent glycated hemoglobin looked like, what side effects you have had, what else you take — especially insulin or an insulin secretagogue, since hypoglycemia risk is a labeled concern with semaglutide in that combination — and what triggered the question, whether that is coverage, cost, supply, or how you feel.

Ask what monitoring is planned around the change and when you should expect to be reassessed. And treat the pharmacy label on whatever you are dispensed as the authority on the product in your hand. That document, and the clinician who wrote the prescription, are the only sources that can tell you how your transition should run.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Is there a dose equivalence between Mounjaro and Ozempic?

No. Neither product's FDA labeling contains a conversion between tirzepatide and semaglutide, and no established equivalence exists. Ozempic's labeled maximum is 2 mg once weekly while Mounjaro's is 15 mg once weekly in adults, but those numbers describe different molecules and are not comparable. How a transition is sequenced is a clinical judgment your prescriber makes, not a table lookup.

Are Mounjaro and Ozempic both weight-loss drugs?

Neither is approved for weight management. Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes. Ozempic's three indications all require type 2 diabetes as well. The weight-management approvals for these molecules belong to different brands — Zepbound for tirzepatide and Wegovy for semaglutide.

Why might a doctor move someone from Mounjaro to Ozempic?

Coverage changes, prior authorization outcomes, pharmacy supply, and cost account for many switches. Clinically, Ozempic carries two indications Mounjaro does not: reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and reducing the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with chronic kidney disease. Tolerability can also differ between individuals.

How different are the two medications?

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist. Semaglutide acts at the GLP-1 receptor only. Switching removes activity at one receptor system entirely, which is why the change is often noticeable, especially for someone who had reached a high tirzepatide dose. That is also why the transition needs a prescriber managing glycemic control and any other diabetes medications alongside it.

Can the two be taken at the same time during a transition?

No. Labeling across this class advises against concomitant use with other GLP-1 receptor agonists, and overlapping a leftover supply with a newly started medication is the most predictable way to cause a serious adverse event. If you have remaining product, including any compounded preparation, disclose it to the clinician managing the change rather than incorporating it into your schedule.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.